Status: Recruiting
A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer
\[18F\]F-AraG is a promising tracer to image activated T-cells with positron emission tomography (PET). The aim of the SHARP trial is to investigate changes in \[18F\]F-AraG uptake following Anti-PD-1 therapy in patients with non-small cell lung cancer (NSCLC).
Participants needed: 15
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Amsterdam UMC, location VUmcUpdated: Mar 28, 2025Locations: 1
Eligibility criteria
Histologically confirmed NSCLC, a histological biopsy is mandatory, negative for... [+7]
Subjects with a condition requiring systemic treatment with either corticosteroi... [+8]